Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate receptor 4 (GRIA4), also known as GluA4, is a subunit of the AMPA-type ionotropic glutamate receptors. These receptors are ligand-gated ion channels that mediate fast excitatory neurotransmission in the central nervous system by responding to the neurotransmitter L-glutamate. AMPA receptors are tetrameric complexes typically formed as heterotetramers from combinations of any of the four subunits (GluA1–GluA4). Each subunit has a large extracellular amino-terminal domain (ATD), a ligand-binding domain (LBD), a transmembrane domain (TMD), and an intracellular C-terminal domain (CTD). GRIA4-containing AMPARs function as ligand-gated cation channels, allowing Na+ influx and K+ efflux upon binding L-glutamate, leading to rapid depolarization in neurons. GRIA4 is highly expressed throughout various regions of the brain including the hippocampal formation, amygdala, basal ganglia, and midbrain. Some haplotypes of GRIA4 have shown positive associations with schizophrenia.
Ligand-gated ion channel activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor 4 (AMPA subtype) (GRIA4).